Lantern Pharma Inc. deeply regrets to announce the death of Dr. Franklyn Prendergast, a director of the Company. The Company learned on October 17, 2023 that Dr. Prendergast had died unexpectedly. Dr. Prendergast had served as a director of the Company since October 2019.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.07 USD | -3.65% | -3.19% | +41.82% |
May. 29 | Transcript : Lantern Pharma Inc. - Special Call | |
May. 24 | Lantern Pharma Files $150 Million Mixed Shelf | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.82% | 65.31M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- LTRN Stock
- News Lantern Pharma Inc.
- Lantern Pharma Inc. Announces the Death of Dr. Franklyn Prendergast, a Director of the Company